Xiamen Zeesan Biotech Co., Ltd.

Established in 2010, Zeesan Biotech has dedicated its expertise to streamlining every step of the diagnostic process, from sample collection, nucleic acid extraction to detection and data analysis.

At the heart of Zeesan Biotech's success lies its innovative MMCA and MeltArray technology, which is protected by a robust patent portfolio. This proprietary technology has enabled the development of unique multiplex nucleic acid detection platforms, catering to a diverse array of applications.

Zeesan Biotech's TB/NTM solutions are at the forefront of molecular diagnostics, addressing the critical need for accurate and efficient detection of tuberculosis (TB) and its drug-resistant strains, as well as the identification of non-tuberculous mycobacteria (NTM). It is currently one of the most comprehensive solutions for drug-resistant TB testing on the market.

By offering this comprehensive suite of integrated services, Zeesan Biotech has positioned itself as a trusted partner for healthcare providers, research institutions, and diagnostic laboratories worldwide. Zeesan Biotech's TB/NTM solutions are currently being utilized in nearly 600 leading medical institutions across China, as well as in over dozens of countries, including India, Indonesia, Thailand, Malaysia, Iran, Pakistan, South Africa, and the United Arab Emirates.